NRx Pharmaceuticals, Inc., a clinical-stage CNS biopharmaceutical company, reported that the independent Data Safety Monitoring Board reviewed the safety and efficacy findings of the first fifty enrolled participants in the Company’s clinical trial of NRX-101 for the treatment of Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior.
